Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
30.00
Dollar change
-0.60
Percentage change
-1.96
%
Index- P/E- EPS (ttm)-13.05 Insider Own26.67% Shs Outstand29.35M Perf Week7.37%
Market Cap880.50M Forward P/E- EPS next Y-2.30 Insider Trans0.70% Shs Float21.52M Perf Month24.48%
Income-57.78M PEG- EPS next Q-0.44 Inst Own43.08% Short Float4.95% Perf Quarter172.73%
Sales1.38M P/S638.04 EPS this Y77.08% Inst Trans10.56% Short Ratio8.11 Perf Half Y125.39%
Book/sh11.40 P/B2.63 EPS next Y-18.85% ROA-35.44% Short Interest1.07M Perf Year131.48%
Cash/sh5.92 P/C5.07 EPS next 5Y- ROE-42.05% 52W Range6.58 - 33.77 Perf YTD188.46%
Dividend Est.- P/FCF- EPS past 5Y29.95% ROI-34.18% 52W High-11.16% Beta1.68
Dividend TTM- Quick Ratio18.42 Sales past 5Y-11.19% Gross Margin3.77% 52W Low355.93% ATR (14)2.42
Dividend Ex-Date- Current Ratio18.42 EPS Y/Y TTM36.64% Oper. Margin-3497.39% RSI (14)62.19 Volatility10.98% 8.84%
Employees53 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin-4183.92% Recom1.17 Target Price47.33
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q86.61% Payout- Rel Volume1.73 Prev Close30.60
Sales Surprise-16.68% EPS Surprise24.47% Sales Q/Q- EarningsMar 21 AMC Avg Volume131.28K Price30.00
SMA2010.39% SMA5028.28% SMA200104.12% Trades Volume227,036 Change-1.96%
Date Action Analyst Rating Change Price Target Change
Feb-15-24Initiated Stifel Buy $44
Dec-26-23Initiated Jefferies Buy $22
Nov-22-23Initiated Wedbush Outperform $23
Oct-30-23Initiated Guggenheim Buy $45
Sep-28-23Initiated Raymond James Outperform $24
Aug-25-22Downgrade Goldman Buy → Neutral $2
Jan-06-22Upgrade Goldman Neutral → Buy $7 → $8
Aug-20-21Resumed Goldman Neutral $7
Aug-03-21Downgrade JP Morgan Overweight → Neutral $16 → $7
Jul-22-21Reiterated B. Riley Securities Buy $21 → $19
Mar-21-24 10:54PM
04:01PM
Mar-07-24 04:30PM
Feb-26-24 07:00AM
Feb-23-24 08:00AM
04:05PM Loading…
Jan-31-24 04:05PM
Jan-22-24 07:30AM
Jan-02-24 08:30AM
Dec-14-23 07:04AM
Nov-29-23 04:05PM
Nov-09-23 04:05PM
Sep-14-23 05:04PM
Aug-14-23 01:35PM
May-03-23 04:19PM
07:00AM
04:10PM Loading…
Mar-31-23 04:10PM
06:09AM
Mar-27-23 10:20AM
Feb-09-23 01:24PM
10:13AM
Feb-03-23 01:35PM
Feb-02-23 04:05PM
05:58AM
Jan-25-23 04:05PM
Dec-21-22 07:39AM
Dec-20-22 11:20AM
09:00AM
Dec-13-22 05:56AM
Dec-12-22 04:30PM
08:00AM
09:01AM Loading…
Nov-03-22 09:01AM
09:01AM
Nov-01-22 08:00AM
Oct-17-22 12:16PM
Sep-23-22 09:15AM
Aug-17-22 08:00AM
Aug-04-22 08:00AM
Aug-02-22 08:00AM
Jul-17-22 09:04AM
May-16-22 12:29PM
09:35AM
08:00AM
May-10-22 11:54AM
Apr-14-22 04:41PM
12:15PM
08:00AM
Mar-08-22 08:00AM
Mar-03-22 08:00AM
Feb-07-22 09:35AM
Jan-18-22 07:00AM
Jan-10-22 08:00AM
Jan-05-22 08:00AM
Dec-14-21 09:00AM
Nov-10-21 06:20AM
Nov-08-21 09:24AM
Nov-04-21 09:10AM
09:09AM
Oct-04-21 08:00AM
Sep-21-21 08:00AM
Sep-15-21 08:00AM
Aug-09-21 06:20AM
Aug-05-21 08:00AM
Aug-03-21 05:30PM
08:00AM
Aug-01-21 11:50AM
Jul-30-21 09:20PM
11:14AM
Jul-28-21 07:39PM
Jul-26-21 08:16PM
Jul-23-21 11:00AM
10:14AM
Jul-21-21 10:30PM
03:46PM
08:47AM
08:00AM
Jul-14-21 10:00AM
Jul-06-21 08:00AM
Jun-17-21 09:43AM
Jun-14-21 08:00AM
Jun-04-21 09:00AM
Jun-03-21 08:00AM
May-14-21 08:00AM
May-12-21 10:00AM
10:00AM
May-06-21 08:00AM
May-03-21 06:41AM
Apr-19-21 08:00AM
Mar-25-21 08:00AM
Mar-15-21 08:00AM
Mar-09-21 08:00AM
Mar-03-21 08:00AM
Feb-27-21 08:08AM
Feb-08-21 08:00AM
Feb-01-21 04:30AM
Jan-11-21 08:00AM
Jan-05-21 08:00AM
Dec-17-20 01:43PM
Dec-07-20 08:00AM
Dec-04-20 11:13AM
08:00AM
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fairmount Funds Management LLCDirectorSep 29 '23Buy13.6324,670336,2521,928,503Oct 03 04:00 PM
Fairmount Funds Management LLCDirectorSep 26 '23Buy13.1530,000394,5001,903,833Sep 28 05:09 PM
Randhawa SimratChief Medical OfficerSep 22 '23Buy13.202,00026,4004,000Sep 25 04:15 PM
Randhawa SimratChief Medical OfficerSep 21 '23Buy13.202,00026,4002,000Sep 25 04:15 PM
Fairmount Funds Management LLCDirectorSep 19 '23Buy13.2030,000396,0001,873,833Sep 21 04:23 PM
Fairmount Funds Management LLCDirectorSep 13 '23Buy11.769,367110,1561,843,833Sep 13 09:17 PM
Fairmount Funds Management LLCDirectorSep 12 '23Buy10.8514,887161,5241,834,466Sep 13 09:17 PM